woman pointing at data on a transparent screen

Investigation into Bioequivalence Study

1 minute read

Published: September 3rd, 2021

A new formulation under investigation was planned to be submitted for use in both the US and Europe. As the reference formulation in the US differs from that in Europe, two separate bioequivalence studies were needed to gain approval from the FDA and EMA. Study 1 was conducted for FDA approval and successfully demonstrated bioequivalence. Study 2 was conducted for EMA approval and whilst AUC was within the bioequivalence limits, Cmax was not, and bioequivalence could not formally be declared.

Complete the form below to read the full case study

Related articles

From Rescue Study to Strategic Partnership: Accelerating Regulatory Submission Through Reliable Statistical Delivery

From Rescue Study to Strategic Partnership: Accelerating Regulatory Submission Through Reliable Statistical Delivery

November 16th, 2026 1 minute read

When clinical development programs face quality concerns, resource shortages, or submission risks, sponsors need a pa...

Turning a Failed Bioequivalence Study into a Successful Regulatory Outcome 

Turning a Failed Bioequivalence Study into a Successful Regulatory Outcome 

November 16th, 2026 1 minute read

When a bioequivalence study fails to meet regulatory criteria, understanding why is critical for successful developme...

Independent DMC Support and Interim Analysis for an ALS Clinical Trial 

Independent DMC Support and Interim Analysis for an ALS Clinical Trial 

November 16th, 2026 1 minute read

Data Monitoring Committees play a vital role in safeguarding patient safety and supporting informed decision-making t...